Exelixis partners with Roche to evaluate advanced solid tumor therapies
Category: #health  By Saipriya Iyer  Date: 2019-12-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

Exelixis partners with Roche to evaluate advanced solid tumor therapies

Exelixis Inc., a California-based drug discovery firm that focuses on discovering, developing and then commercializing drugs for cancer treatment, recently announced that it has inked an agreement to collaborate with Roche for the evaluation of cabozantinib (CABOMETYX®), Exelixis’ molecule inhibitor of the receptor tyrosine, combined with PD-L1 immune checkpoint inhibitor, tezolizumab (TECENTRIQ®) for patients suffering from advanced or metastatic solid tumors.

Apparently, having co-funded by the firms, the clinical program shall include about three Phase 3 pivotal trials for advanced castration-resistant prostate cancer (CRPC), renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC).

Exelixis’ Chief Executive Officer and President, Michael M. Morrissey, Ph.D., commented that the promising data for Phase 1 indicates that the combination of both atezolizumab and cabozantinib will help in the improvement of outcomes in patients suffering from lung, kidney and prostate cancers. The company looks forward to collaborating with Roche and learning more during these pivotal trials.

Morrissey further added that the clinical collaboration will be marked as an important step in the company’s devoted efforts to be able to maximize cabozantinib franchise’s value via the cost-sharing clinical partnership within the added high-impact indications and also developing value with newer compounds from both external and internal sources in the year 2020 and after.

Seemingly, the collaborations in the clinical development have been building on the promising activity that was observed in the phase 1b COSMIC-021 trial. The study has been taking in about 24 expansion cohorts in 12 different tumor types which include NSCLC, CRPC and RCC.

TECENTRIQ® (atezolizumab) is essentially Genentech’s registered trademark which is a member of the Roche Group.

The U.S. has given CABOMETYX tablets an approval to be used in the treatment of patients suffering from advanced RCC as well as the treatment of patients suffering from hepatocellular carcinoma and have been treated with sorafenib.

Source Credit- https://ir.exelixis.com/news-releases/news-release-details/exelixis-enters-clinical-collaboration-three-phase-3-combination



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Foodics enters Egypt market by setting an on-ground presence in Cairo
Foodics enters Egypt market by setting an on-ground presence in Cairo
By Saipriya Iyer

Saudi Arabia-based restaurant management platform Foodics, has announced that it has entered the Egyptian market by creating an on-the-ground presence in Cairo.  The expansion comes after the company raised USD 4 ...

Food Emulsifiers Market to Witness an Appreciable Growth By 2026
Food Emulsifiers Market to Witness an Appreciable Growth By 2026
By Saipriya Iyer

This advanced report on the Food Emulsifiers Market includes of an in-depth overview of this business sphere. Alongside, details of the present market size and status have been given. The report aims to provide substantial updates on the market, p...

Bharat Biotech reveals positive data from animal trial of Covaxin
Bharat Biotech reveals positive data from animal trial of Covaxin
By Saipriya Iyer

Bharat Biotech, an Indian biotechnology company, has reportedly revealed positive results from the animal trial of Covaxin, India’s COVID-19 vaccine candidate.

In the animal t...